HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
Background & Aims: Risk scores have been designed to predict the development of hepatocellular carcinoma (HCC) in treatment-naive patients with chronic hepatitis B (CHB).However, little is known about their predictive accuracy in HBeAg-negative patients in the grey zone (GZ).We aimed to develop a HBcrAg-based HCC risk score and explore whether